15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Unicycive Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $15.00 to $50.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $25.00 sits 396% above the current $5.04. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.34 next quarter toward $1.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Unicycive Therapeutics Inc.
As of Sep, 5 of 5 firms rate UNCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
UNCY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.34
Range $-0.43 – $-0.25 · 8 analysts · -58% YoY
Next period, 8 analysts expect Unicycive Therapeutics Inc to earn $-0.34 a share (range $-0.43 – $-0.25), versus $-0.82 a year earlier. Full-year consensus is $-1.21, growing to $1.41 the year after.
REVENUE · NEXT QUARTER
$275.4K
Range $0 – $1.7M · 8 analysts
Revenue is expected to reach $275.4K (range $0 – $1.7M). Full-year consensus is $275.4K, rising to $145.4M next year.
Top analysts covering Unicycive Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UNCY.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$20.00+296.8% to target
Overall win rate
50%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$7.50+48.8% to target
Overall win rate
44%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$90.00+1685.7% to target
Overall win rate
33%
+ Follow
#4
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$15.00+197.6% to target
Overall win rate
38%
+ Follow
#5
Bruce Jackson
Benchmark · Rank #374
Buy
$15.00+197.6% to target
Overall win rate
36%
+ Follow
UNCY stock forecast FAQ
What is UNCY's average 12-month price target?+
The 5 analysts with a live target average $25.00 for Unicycive Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $15.00 low.
Is UNCY stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for UNCY?+
The Street-high target is $50.00 (Noble Capital Markets), and the Street-low is $15.00 (Benchmark). The average of all 5 active targets is $25.00.
How many Wall Street analysts cover UNCY?+
5 analysts have an active rating on Unicycive Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering UNCY?+
Among analysts who currently cover UNCY, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $20.00 target.
What is Unicycive Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.34 per share (range $-0.43 – $-0.25) across 8 analysts. Full-year EPS is projected at $-1.21, rising to $1.41 the following year.
How much revenue is Unicycive Therapeutics Inc expected to report next quarter?+
Consensus revenue is $275.4K (range $0 – $1.7M). Full-year revenue is projected at $275.4K, growing to $145.4M next year.
Have analysts been upgrading or downgrading UNCY lately?+
As of Sep, 5 of 5 firms rate UNCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UNCY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
